Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • Bitcoin USD

    62,974.81
    +3,694.26 (+6.23%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • Dow

    38,675.68
    +450.02 (+1.18%)
     

  • Nasdaq

    16,156.33
    +315.37 (+1.99%)
     

  • Gold

    2,310.10
    +0.50 (+0.02%)
     

  • Crude Oil

    77.99
    -0.96 (-1.22%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Monopar Therapeutics Inc.
·1-min read
Monopar Therapeutics Inc.
Monopar Therapeutics Inc.

WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.

Meeting Details:

Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting

ADVERTISEMENT

Date: June 8 – June 11, 2024

Location: Metro Toronto Convention Centre, Toronto, ON, Canada

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: www.monopartx.com and ir.monopartx.com/presentations.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics